Background. Pompe disease (PD) is a genetic orphan progressive multisystem neuromuscular disorder that belongs to the group of lysosomal storage diseases and often leads to death. The only treatment available is lifelong enzyme replacement therapy (ERT). Early diagnosis and early initiation of ERT prevent the development of PD manifestations. The purpose was to present the latest advances in the study of the pathogenesis, diagnosis, and clinical course of PD, as well as new directions in its treatment, to describe a clinical case of managing a child with PD at the Municipal Non-Profit Enterprise “Regional Clinical Children’s Hospital of the Kirovohrad Regional Council” in Kropyvnytskyi, and also to demonstrate the need for the use of new ERT agents in Ukraine. Materials and methods. Contemporary literature in Scopus, Web of Science, PubMed and other databases was analyzed. A clinical case of infantile-onset Pompe disease is presented. The registry of the Pompe Disease Center at the Erasmus University Rotterdam (Netherlands) was reviewed. Results. New directions in the study of PD pathogenesis (including autophagy disorders), the development and use of new ERT agents have been highlighted. A clinical case of an infantile-onset PD and the results of ERT use were analyzed: within one year of therapy, the child demonstrated improvement in general condition, re-emergence of previously lost motor skills, and reduction of cardiomyopathy signs. However, recovery of skeletal muscle function remained very slow, which led to the development of contractures. The emergence of new agents for PD therapy, whose effect on skeletal muscles is much better, offers prospects for improving the patient’s quality of life. Conclusions. Diagnosis of PD is challenging but feasible in Ukraine. Treatment consists of lifelong ERT, which should be initiated as early as possible. To ensure timely diagnosis, incorporation of acid α-glucosidase testing into neonatal genetic screening is advisable. According to the Erasmus University Rotterdam PD registry, the patient’s prognosis is potentially less severe; however, based on the clinical course, the child requires the use of new ERT agents.